Lymphokine Patents (Class 424/85.1)
  • Patent number: 11117969
    Abstract: This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified ?1-?2 domains of NKG2D ligands. This application further relates to modified ?1-?2 domains of NKG2D ligands attached to polypeptides, in some embodiments antibodies or fragments of antibodies. This application further relates to antigen-binding peptides derived from light and heavy chain antibody variable domains, which contain two linker regions and a split variable domain.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: September 14, 2021
    Assignee: XYPHOS BIOSCIENCES INC.
    Inventors: Kyle Landgraf, Daniel P. Steiger, Steven R. Williams, David W. Martin, Jr., Dana Gebhart, Tarah Baron
  • Patent number: 11117942
    Abstract: Compositions and methods are provided for treating companion animals are provided. An adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding erythropoietin (EPO). In desired embodiments, the subject is a cat or dog.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: September 14, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Christian Hinderer, James M. Wilson, Matthew Wilson
  • Patent number: 11103524
    Abstract: The present invention concerns a solid, palatable composition and its preparation process which, relative to the total weight of the composition, comprises: 5 to 30%, preferably 8 to 20% by weight of at least one fat chosen from among a liquid oil, a fat, wax or mixture thereof, the liquid oil not to represent more than 8% by weight of the composition; 0.001 to 85% by weight of at least one active substance; and 20 to 95%, preferably 40 to 70% by weight of at least one palatable material, for use thereof as medicinal product, nutraceutical or food supplement, for oral administration to mammals, except man, in particular for domestic animals such as dogs, cats or horses. The said solid composition is obtained by mixing the components, vaporising the fats, calibrating the dry, fluid granular material and compressing the granular material in a stock cube press.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: August 31, 2021
    Assignee: Friulchem Spa
    Inventors: Guy Derrieu, Giancarlo Mazzola
  • Patent number: 11098106
    Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: August 24, 2021
    Assignee: Axon Neuroscience SE
    Inventors: Michal Novák, Eva Kontseková, Branislav Kovácech, Norbert Zilka
  • Patent number: 11083788
    Abstract: The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: August 10, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James R. Baker, Jr., Anna U. Bielinska, Douglas Smith, Paul E. Makidon, Jessica J. O'Konek
  • Patent number: 11085088
    Abstract: The present disclosure provides for and relates to cancer treatment based on the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: August 10, 2021
    Assignees: HudsonAlpha Institute for Biotechnology, BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Richard M Myers, James D Brooks, Marie K Kirby
  • Patent number: 11046759
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: June 29, 2021
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West
  • Patent number: 11045500
    Abstract: A three-dimensional fibrin engineered tissue construct is provided selected from: (i) a fibrin gel matrix comprising a combination of tissue-specific cells and at least one type of vascular cells; and (ii) a hybrid scaffold of fibrin gel and a polymeric synthetic scaffold comprising at least one type of vascular cells or a combination of tissue-specific cells and at least one type of vascular cells.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: June 29, 2021
    Assignee: TECHNION RESEARCH DEVELOPMENT FOUNDATION LTD.
    Inventors: Shulamit Levenberg, Ayelet Lesman
  • Patent number: 11047858
    Abstract: A method for detecting and typing rare tumor cells having high metabolic activity in a body fluid sample, comprising the following steps: incubating nucleated cells in a body fluid sample with a first metabolic marker and a second metabolic marker capable of producing fluorescence signals; detecting, by means of high-throughput imaging, uptake of all the fluorescence signals of the metabolic markers by cells, so as to determine the energy metabolism mode and intensity of the cells; and identifying and typing, according to the fluorescence signals of the metabolic marker combination, tumor cells having high metabolic activity in the body fluid sample. Further provided is a kit used for the detecting and typing method, comprising a microwell array chip, a first metabolic marker and a second metabolic marker capable of producing fluorescence signals, and fluorescence-labeled antibodies specific to leukocyte common antigen.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: June 29, 2021
    Assignee: Suzhou Junhui Biotechnology Co., Ltd.
    Inventors: Qihui Shi, Yuliang Deng, Yin Tang, Zhuo Wang
  • Patent number: 11040110
    Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: June 22, 2021
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Dae Hae Song, Jae Hee Shin, Mi Ji Lee, Sung Hee Hong, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 10982190
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: April 20, 2021
    Assignee: SDF BioPharma Inc.
    Inventors: Gerald F. Swiss, David Kiewlich
  • Patent number: 10967008
    Abstract: The present invention relates to methods for the preparation of compositions comprising adipose tissue-derived secretions, for example those derived from bovine adipose tissue, and the use of such compositions in the preparation of a pharmaceutical composition for topical use. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of a non-inflammatory condition, for example the treatment of a skin condition, and for the stimulation of hair growth in a subject by topical application. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of acne.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: April 6, 2021
    Assignee: Cell Ideas Pty Ltd
    Inventors: Graham Vesey, Rebecca Anne Webster
  • Patent number: 10960064
    Abstract: NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to remove checkpoint inhibitory receptor expression and/or add mutant (variant) TRAIL ligand expression.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: March 30, 2021
    Assignee: ONK THERAPEUTICS LIMITED
    Inventor: Michael O'Dwyer
  • Patent number: 10906957
    Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGF? trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: February 2, 2021
    Assignee: EpicentRx, Inc.
    Inventors: Christopher Larson, Tony R. Reid, Bryan T. Oronsky
  • Patent number: 10882911
    Abstract: Disclosed is a CD154 binding polypeptide that specifically recognizes CD154. The polypeptide according to the present disclosure effectively inhibits the CD154-CD40 interaction without activating platelets, and thus can be effectively used in the prevention or treatment of various T cell-mediated or antibody-mediated diseases or symptoms, which requires inhibition of the interaction.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: January 5, 2021
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: SeongHoe Park, Kyeong Cheon Jung
  • Patent number: 10883116
    Abstract: The invention relates to transduction compounds, buffers and methods for introducing molecules into cells. The invention also relates to methods of treatment, pharmaceutical compositions and other uses of the transduction compounds and buffers. The invention also relates to modified cells obtainable by the transduction compounds, buffers and methods of the invention.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: January 5, 2021
    Assignee: Koninklijke Nederlandse Akademie van Wetenschappen
    Inventors: Niels Geijsen, Diego Sebastián D'Astolfo
  • Patent number: 10869887
    Abstract: Engineered orthogonal cytokine receptor/ligand pairs, and methods of use thereof, are provided.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: December 22, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kenan Christopher Garcia, Jonathan Sockolosky, Lora Picton
  • Patent number: 10842743
    Abstract: Hyaluronic acid-based hydrogels, solutions for preparing such, and methods pertaining thereunto are disclosed with properties that include self-resorption, extended release of biologically active agents, and/or decreased degradation, denaturation, and/or functional inactivation of biologically active agents.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: November 24, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael D. Roth, Airi Harui
  • Patent number: 10835596
    Abstract: Compositions of a recombinant adenovirus based vector vaccine containing one or more flavivirus antigen genes are disclosed herein. Methods for constructing and producing such vaccines and methods of using these vaccines to generate immune responses against flaviviruses are also described. Compositions described herein allow for vaccinations in subjects with preexisting immunity to adenovirus.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: November 17, 2020
    Assignee: Etubics Corporation
    Inventors: Frank R. Jones, Joseph Balint, Adrian Rice, Yvette Latchman, Elizabeth Gabitzsch
  • Patent number: 10801065
    Abstract: Provided herein are methods of determining a subject's level of exposure to radiation and methods of determining a subject's risk of subsequent development of radiation disease or risk of poor prognosis from radiation exposure that include determining a level of one or more miRNAs selected from the group consisting of mouse and human homologues of mouse miR-130a-3p, miR-150-5p, miR-17-3p, miR-187-3p, miR-194-5p, miR-27a-3p, miR-30a-3p, miR-30c-5p, miR-142-5p, miR-342-3p, miR-34b-3p, miR-126-3p, miR-320-3p, miR-136-5p, miR-33-5p, miR-142a-3p, miR-706, miR-375-3p, miR-29a-5p, miR-193a-3p, miR-99b-5p, miR-151-3p, miR-let-7d-3p, miR-486-5p, miR-423-5p, miR-30b-5p, miR-191-5p, miR-497a-5p, miR-32-5p, miR-214-5p, miR-326-3p, miR-1195, miR-122-5p, miR-1839-3p, miR-500-3p, miR-30e-3p, miR-322-3p, miR-709, miR-486-3p, miR-133a-3p, miR-676-3p, miR-744-5p, miR-29a-3p, miR-1839-5p, miR-30a-5p, miR-199b-5p, miR-125a-5p, miR-133b-3p, miR-24-3p, miR-21a-5p, miR-503-5p, miR-328-3p, miR-let-7g-5p, miR-362-3p, miR-199a-5p, miR
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: October 13, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Albert Einstein College of Medicine, Inc.
    Inventors: Dipanjan Chowdhury, Chandan Guha
  • Patent number: 10792338
    Abstract: A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: October 6, 2020
    Assignee: Remedor Biomed Ltd.
    Inventor: Saher Hamed
  • Patent number: 10787643
    Abstract: The present invention relates to methods and kits for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods, kits, and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: September 29, 2020
    Assignee: STOWERS INSTITUTE FOR MEDICAL RESEARCH
    Inventors: John M. Perry, Linheng Li, Justin C. Grindley
  • Patent number: 10722537
    Abstract: Provided herein are methods of treating cancer by activating resident memory T cells using one or more antigenic peptides.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: July 28, 2020
    Assignee: Regents of the University of Minnesota
    Inventors: David B. Masopust, Jr., Vaiva D. Vezys
  • Patent number: 10696725
    Abstract: The present invention relates to a glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: June 30, 2020
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk Kim, Young Jin Park, In Young Choi, Sung Youb Jung
  • Patent number: 10690677
    Abstract: Methods for identifying compounds that modulate cellular responses stimulated by IgE, which include providing an impedance-based system that monitors cell-substrate impedance of cells on a substrate; introducing cells to the substrate of the system; adding at least one test compound and IgE to the cells, wherein the at least one test compound is suspected of modulating cell responses stimulated by the IgE; adding an antigen to the cells; monitoring the cell-substrate impedance of cells on the substrate; and analyzing the cell-substrate impedance to evaluate whether the at least one test compound alters a cellular response to stimulation with the IgE.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: June 23, 2020
    Assignee: ACEA Biosciences, Inc.
    Inventors: Xiao Xu, Yama A. Abassi, Xiaobo Wang, Jiangbo Gan
  • Patent number: 10622675
    Abstract: A solvent useful for lithium batteries comprises a compound of Formula (I): (R1)(R2)(R3)Si—R4—O—C(O)—[(O—R5)n—(O—C(O)]m—O—R6—X1. Each of R1 and R2 independently is alkyl; R3 is alkyl, —X2—Si(R7)(R8)(R9), or —CH2—O—C(O)—O—R10; X1 is H or —Si(R11)(R12)(R13); each of R4 and R6 independently is alkylene; each R5 independently is C2 to C6 alkylene; each of R7, R8, R9, and R10 independently is alkyl; X2 is O or alkylene; each of R11 and R12 independently is alkyl; R13 is alkyl or —X3—Si(R14)(R15)(R16); each of R14, R15, and R16 independently is alkyl; X3 is O or alkylene; m is 0 or 1, and n is 1-3; and when m is 0 and R3 is alkyl, X1 is —Si(R11)(R12)(R13). Also described is a method for manufacturing a compound of Formula (II): (R17)(R18)(R19)Si—CH2—O—C(O)—O—R20 where each R17, R18, R19, and R20 is alkyl.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: April 14, 2020
    Assignee: UCHICAGO ARGONNE, LLC
    Inventors: Trevor L. Dzwiniel, Krzysztof Pupek, Gregory K. Krumdick
  • Patent number: 10617689
    Abstract: The present invention relates to compositions and methods for controlling glycaemia in a mammalian in need thereof. The present invention relates to compositions and methods for the treatment of diabetes disease and related disorders. More specifically, the present invention relates to novel therapies or combinatorial therapies of diabetes and related disorders, based on compositions controlling the blood glucose level.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: April 14, 2020
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Rodolphe Hajj
  • Patent number: 10610570
    Abstract: This document provides methods and materials related to treating rotator cuff conditions (e.g., rotator cuff tendonitis or rotator cuff injuries such as partial rotator cuff tears). For example, methods and materials for using BMP-5 polypeptides to treat rotator cuff conditions as well as methods and materials for using inhibitors of SIRT6, SIRT7, and/or HDAC10 polypeptide expression or activity to treat rotator cuff conditions are provided.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: April 7, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Scott M. Riester, John W. Sperling, Andre J. van Wijnen
  • Patent number: 10611830
    Abstract: The present invention provides an antibody or antibody fragment for specifically recognizing and binding to an ED-B domain of fibronectin. The antibody or antibody fragment can be widely used for in vitro detection and in vivo location of the ED-B protein domain, as well as targeted therapy of tumors.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: April 7, 2020
    Assignee: HEFEI LIFEON PHARMACEUTICAL CO. LTD.
    Inventors: Junqiu Ji, Mei Zhang, Meihua Gao, Jun Chen
  • Patent number: 10583182
    Abstract: The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF/TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.
    Type: Grant
    Filed: February 11, 2018
    Date of Patent: March 10, 2020
    Inventor: Atsuo Ochi
  • Patent number: 10570206
    Abstract: The present invention relates in general to the field of TNF ligand family members. In more detail the present invention relates to polypeptides comprising at least three components A, each of which comprises the sequence of a TNF homology domain (THD) of a TNF ligand family member, or a functional derivative thereof, and comprising at least one component B consisting of a VL region and a VH region linked directly to each other with a linker sequence L which has a length of <12 amino acids. Furthermore, the present invention also relates to nucleic acids encoding such polypeptides and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: February 25, 2020
    Assignee: UNIVERSITAT STUTTGART
    Inventors: Klaus Pfizenmaier, Roland Kontermann, Martin Siegemund
  • Patent number: 10556963
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: February 11, 2020
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Tim Beaumont, Marijn Aletta Gillissen, Adrianus Quirinus Bakker, Mette Deborah Hazenberg, Martijn Kedde
  • Patent number: 10555963
    Abstract: Disclosed is the use of a klotho protein or related compounds (especially KL1 or KL1 analogue) for treatment, and especially treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents.
    Type: Grant
    Filed: March 25, 2012
    Date of Patent: February 11, 2020
    Assignee: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Ido Wolf, Tamar Rubinek, Bella Kaufman, Lilach Abramovitch
  • Patent number: 10556009
    Abstract: The present invention relates to pharmaceutical formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, a buffering agent and a tonicity agent.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: February 11, 2020
    Assignee: GlaxoSmithKline Intellectual Property Management Limited
    Inventors: Angela Blake-Haskins, Tristan Marshall, Melissa D. Perkins, Kristin O'Berry
  • Patent number: 10537915
    Abstract: An illustrative embodiment of a contaminant resistant structure includes a substrate having a substrate surface, at least one contaminant resistant material provided on the substrate surface and a hydrophobic or oleophobic, and alternatively, a hydrophilic or oleophilic material provided on at least a portion of the substrate surface.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: January 21, 2020
    Assignee: The Boeing Company
    Inventors: Shawn Park, John Belk
  • Patent number: 10532045
    Abstract: Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: January 14, 2020
    Assignee: Signpath Pharma, Inc.
    Inventors: Lawrence Helson, George M. Shopp, Annie Bouchard
  • Patent number: 10521911
    Abstract: A method of reviewing neural scans includes receiving at least one landmark corresponding to an anatomical region. A plurality of images of tissue including the anatomical region is received and a neural network configured to differentiate between healthy tissue and unhealthy tissue within the anatomical region is generated. The neural network is generated by a machine learning process configured to receive the plurality of images of tissue and generate a plurality of weighting factors configured to differentiate between healthy tissue and unhealthy tissue. At least one patient image of tissue including the anatomical region is received and a determination is made by the neural network whether the at least one patient image of tissue includes healthy or unhealthy tissue.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: December 31, 2019
    Assignee: Siemens Healtchare GmbH
    Inventors: Benjamin L. Odry, Hasan Ertan Cetingul, Mariappan S. Nadar, Puneet Sharma, Shaohua Kevin Zhou, Dorin Comaniciu
  • Patent number: 10513549
    Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: December 24, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason G Sagert
  • Patent number: 10487421
    Abstract: The present disclosure discloses reinforced electrospun fibrous membranes and preparation methods therefor. The reinforced electrospun fibrous membranes can include an electrospun fibrous membrane body and a plurality of reinforcing thread sets fixed to the electrospun fibrous membrane body through holes thereon, wherein any two of the plurality of reinforcing thread sets are parallel to each other; each of the reinforcing thread sets comprises a starting end and a terminal end, both being connected to an edge of the electrospun fibrous membrane body; each of the reinforcing thread sets comprises at least one reinforcing fibrous thread consisting of a main thread and an auxiliary thread respectively arranged at a front side and a bottom side of the electrospun fibrous membrane body and configured to interlace each other at the through hole.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: November 26, 2019
    Assignee: Medprin Regenerative Medical Technologies Co., Ltd.
    Inventors: Guangyao Li, Kunxue Deng, Yaya Yang, Yuyu Yuan
  • Patent number: 10471110
    Abstract: This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction, dilated cardiomyopathy, inflammatory heart disease (including endocarditis, inflammatory cardiomegaly and myocarditis), and congestive heart failure.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: November 12, 2019
    Assignee: DuPont Nutrition Biosciences ApS
    Inventors: Lotta Stenman, Sampo Lahtinen, John Konhilas
  • Patent number: 10464982
    Abstract: This disclosure relates to recombinant proteins comprising a GM-CSF sequence and an interleukin sequence and nucleic acids related thereto. In certain embodiments, the disclosure relates to recombinant proteins comprises N-terminal sequences that are the result of improved production techniques and uses for treating or preventing autoimmune diseases such as multiple sclerosis and cancer.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: November 5, 2019
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Jacques Galipeau, Andrea Pennati
  • Patent number: 10463598
    Abstract: The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleansing composition, e.g., a composition in which capsaicin is soluble.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: November 5, 2019
    Assignee: Averitas Pharma Inc.
    Inventors: Arturo J. Angel, Larry W. Litle, Keith R. Bley, Allan L. Wilcox, Gene C. Jamieson, Naweed Muhammad
  • Patent number: 10456451
    Abstract: The present invention features mutant stromal cell derived factor-1 (SDF-1) peptides that have been mutated to make them resistant to digestion by, for example, the proteases dipeptidyl peptidase IV (DPPIV), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), leukocyte elastase, cathepsin G, carboxypeptidase M, and carboxypeptidase N, but which retain chemoattractant activity.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 29, 2019
    Assignee: Mesoblast International Sàrl
    Inventors: Vincent Frans Maria Segers, Anthony Sandrasagra, Yan Qiu
  • Patent number: 10434188
    Abstract: The present invention provides fusion proteins including a hyaluronic acid-binding domain of a cartilage matrix protein and a conserved region of a growth factor protein. Certain embodiments provide nucleic nucleic acid sequences encoding a fusion protein and compositions thereof. Methods for using fusion polypeptides and nucleic acid molecules discloses herein are also provided. In certain embodiments, the fusion proteins and/or nucleic acid molecules can be used to treat a cartilage matrix protein-related condition in a subject.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: October 8, 2019
    Assignees: THE TRUSTEES OF INDIANA UNIVERSITY, UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Stephen B. Trippel, Shuiliang Shi
  • Patent number: 10426800
    Abstract: The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: October 1, 2019
    Assignee: CELL4VET CORPORATION
    Inventors: Ching Shwun Lin, Tom F. Lue, Guiting Lin
  • Patent number: 10420744
    Abstract: The present invention is directed compositions derived from green coffee bean extract and methods for the use and manufacture of such compositions. The compositions of the invention have unique ratios of chlorogenic acids which offer a therapeutic effect in the treatment of a variety of conditions and disorders. Methods for using the compositions of the invention include, but are not limited to, methods for treating obesity and methods for regulating serum lipids.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: September 24, 2019
    Assignee: Vidya Herbs, Inc.
    Inventors: Kodimule Shyam Prasad, Harakanahalli Lingaraju Basavegowda
  • Patent number: 10421796
    Abstract: Lysine-depleted variants of fragment crystallizable (Fc) regions of immunoglobulins are disclosed. Also disclosed are fusion proteins comprised of N-terminal targeting or active peptide domains fused with such lysine-depleted variant IgG-Fc domains. Polynucleotides encoding such proteins, compositions and kits containing such proteins, and methods of using such proteins are also disclosed.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: September 24, 2019
    Inventor: Gray D Shaw
  • Patent number: 10400242
    Abstract: Compositions and methods for treating acute myeloid leukemia (AML) based on upregulating expression of microRNA-22 (miR-22), and a nanoparticle delivery system that utilizes FLT3-functionalized polyamidoamine (PAMAM) dendromirs for targeted delivery of miR-22 and/or agents that upregulate expression of miR-22 to AML cells.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: September 3, 2019
    Assignee: University of Cincinnati
    Inventors: Jianjun Chen, Xi Jiang
  • Patent number: 10398772
    Abstract: Compositions including a therapeutically effective amount of an HIV immunogen in combination with an agent that stimulates the Ras pathway, wherein the agent is not an aluminum salt, are disclosed. Methods are also disclosed for inducing an immune response to HIV, and/or to inhibit or treat HIV infection, in a subject, using an HIV immunogen and an agent that stimulates the Ras pathway. Methods also are disclosed for determining if an immunogenic composition will induce a protective response, and/or to determine if an immunogenic composition is of use to prevent or treat an HIV infection. The methods including determining if the immunogenic composition increases the level of one or more components of the Ras signaling pathway.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: September 3, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Oregon Health & Science University
    Inventors: Genoveffa Franchini, Rafick-Pierre Sekaly, Slim Fourati, Mark Cameron, Monica Vaccari, Luca Schifanella, Shari Gordon, Melvin Doster, Namal Malimbada Liyanage
  • Patent number: 10371705
    Abstract: The present invention provides a humanized antibody or antibody fragment comprising (a) a humanized light chain comprising 1) Complementarity Determining Region (CDR)-L1, the sequence of which is identical to the sequence of SEQ ID NO: 3; 2) CDR-L2, the sequence of which is identical to the sequence of SEQ ID NO: 4; and 3) CDR-L3, the sequence of which is identical to the sequence of SEQ ID NO: 5, and (b) a humanized heavy chain comprising 1) CDR-H1, the sequence of which is identical to the sequence of SEQ ID NO: 6; 2) CDR-H2, the sequence of which is identical to the sequence of SEQ ID NO: 7; and 3) CDR-H3, the sequence of which is identical to the sequence of SEQ ID NO: 8, as well as methods for treating, diagnosing, and monitoring the progression of HIT. The present invention also provides methods for assessing the antigenicity and ability to cause HIT of anionic anticoagulants.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: August 6, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, Douglas B. Cines, Zheng Cai, Zhiqiang Zhu